Physician profile

Michael A Rihner

Cardiovascular Disease · Mobile, AL

NPI 1831279702

$12,862.64

in general payments reported to CMS, 2019-2025

42 companies · $608 in 2025

The $608 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,854.43

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $5,577.06 2019-2022
Novartis Pharmaceuticals Corporation $1,553.30 2019-2025
Janssen Pharmaceuticals, INC $1,425.40 2019-2023 Xarelto
Boehringer Ingelheim Pharmaceuticals, INC. $484.71 2019-2023 Jardiance
Sanofi-Aventis U.S. LLC $468.46 2019-2024
E.R. Squibb & Sons, L.L.C. $365.17 2019-2025 Camzyos, Eliquis
Amgen INC. $304.24 2019-2023 Repatha
Biotronik INC. $250.67 2022-2023 Orsiro Mission
Boston Scientific Corporation $219.78 2019-2023 Watchman Flx, Watchman Access System
Abbott Laboratories $196.33 2025 Jot Dx, Mitraclip
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $196.02 2019-2021
Astellas Pharma US INC $188.17 2019-2021
Amarin Pharma, INC. $166.94 2019-2022
Merck Sharp & Dohme LLC $149.33 2024-2025 Verquvo
Medtronic, INC. $130.17 2021-2025 Symplicity G3
Show all 42 companies
CompanyGeneral paymentsYearsTop products
Arbor Pharmaceuticals, INC. $113.62 2019-2021
Novo Nordisk INC $109.61 2022-2025 Ozempic, Rybelsus
Gilead Sciences, INC. $98.94 2019
Pfizer INC. $94.95 2020-2024
Altathera Pharmaceuticals LLC $70.14 2021
Lexicon Pharmaceuticals, INC. $67.05 2024
Kiniksa Pharmaceuticals International, Plc $63.41 2024 Arcalyst
Esperion Therapeutics, INC. $63.38 2020-2021
Lundbeck LLC $54.69 2019-2020
Daiichi Sankyo INC. $53.21 2021-2023 Injectafer
Scpharmaceuticals INC. $49.65 2025
Regeneron Healthcare Solutions, INC. $46.95 2019
Irhythm Technologies, INC. $38.21 2023 Zio Xt Patch
Inspire Medical Systems, INC. $33.15 2024 Inspire
Kowa Pharmaceuticals America, INC. $25.38 2019-2020
Abiomed $23.33 2019
Vivaquant INC, Dba Rhythm Express $21.84 2024 Rhythm Express
Actelion Pharmaceuticals US, INC. $21.35 2022
Lantheus Medical Imaging, INC. $18.77 2023 Definity
Cardiofocus, INC. $18.28 2019
Cardiva Medical, INC. $16.96 2025 Cardiva Vascade Mvp Vvcs 6-12f
Bayer Healthcare Pharmaceuticals INC. $16.13 2022
Biosense Webster, INC. $15.80 2021
Medtronic Vascular, INC. $15.33 2020
Kiniksa Pharmaceuticals, LTD. $13.44 2023 Arcalyst
Vifor Pharma, INC. $13.12 2019
Phathom Pharmaceuticals, INC. $10.20 2025 Voquezna

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael A Rihner

$12,862.64

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $608 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/309959/michael-a-rihner

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.